The firm is an East Coast-based early-stage fund founded in 2019. The firm is affiliated with, but separate from, a leading university leveraging the network of schools and 70,000 + alumni network to help their portfolio companies. The firm invests in technology-based companies in the pre-seed and seed stage, and while they prefer the companies have some revenue, they will invest in pre-revenue companies. The firm invests in several verticals, including SilverTech™ (Seniors and Tech), PropTech, Fintech, Cybersecurity HealthTech and AI/ML. The firm does not invest in therapeutics or medical devices. The firm invests in North America and in Israel, with check size between $50-150K into rounds with a pre-money valuation of $2-10M.
Within HealthTech, the firm invests in SilverTech™ and digital health. For digital health, the company is interested primarily in B2B models, but will invest in B2B2C as well. The firm has a special interest in Agetech, as one of the GPs is third generation senior living owner/operator.
The firm does not lead rounds, but is a very active investor alongside top-tier funds. Due to their strategic value, they are asked to serve in an advisory capacity. The firm prides itself on being a valued strategic partner. The firm will invest in new or seasoned entrepreneurs, who have assembled exceptional teams.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Everything You Need to Start Partnering Today
By Karen Deyo, Director of Investor Research, Israel BD, LSN
Digital RESI March partnering is now open! While it may seem like a simple task to book meetings, successful partnering is a process that takes time, effort, and careful strategy. With over 40 events across a decade, Life Science Nation (LSN) knows how to partner like a pro and offers many free resources, including fundraising bootcamps and informational articles designed to help startups succeed.
RESI attendees also have an added benefit of an investor profile based on the content of the LSN Investor Database, and reading it thoroughly is critical – make sure you are a fit for the investor before reaching out. Additionally, craft a message that is clear and concise with enough information to whet the investor’s appetite for more. Most importantly, follow up!
If you find yourself needing help, or even if you just want to see if there is a new trick for you to learn, read one of the articles we’ve written about partnering in the links below, or sign up to attend our free webinar, Strategies For Successful Partnering, taking place on Tuesday, March 8 at 12PM EST. Happy partnering!
- Preparing for Investor Outreach
- When an Investor Won’t Respond
- How to Craft a Follow Up Strategy
- Getting Ready for Partnering Meetings
There’s still time to sign up – register here for a chance to meet with the 300+ investor attendees who will take part in Digital RESI March!
Digital RESI June
By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the LSN Partnering Conference Series
Part of the success of the Redefining Early Stage Investments (RESI) conference series over the past decade includes its flexible structure and ability to provide valuable partnering resources to early-stage companies and investors alike. While there is no substitute for in-person meetings, RESI’s virtual platform has provided attendees with ease of access around the world. This is why, moving into the new year, RESI will return with both virtual and in-person formats – providing attendees with options to fit their needs.
Digital RESI returns June 7-9 in a virtual format to provide a web-based partnering option to global attendees. RESI Boston will kick off the first in-person event September 20-22, 2022. There is no one-size-fits-all event structure that meets the needs and goals of fundraising executives, early-stage investors, and the many valuable service providers in life science and healthcare, but RESI provides options to attendees who do not need to sacrifice their goals and priorities in 2022 and keeps its promise to connect startups to the early-stage capital and channel partners they need.
Hot Investor Mandate: USA-Based Investment Firm Most Interested in Companies Intersecting Life Sciences and Technology, Such as AI-Enabled Drug Discovery
A USA-based firm makes early-stage investments in cloud computing, E-commerce, AI, aerospace engineering, and biotechnology. The firm typically engages in seed to series A investment rounds. The firm is open to companies based around Seattle, Oregon, and is recently looking into the Greater Boston areas. The firm tends to be a co-investor.
The firm is most interested in the cross sector of IT and life sciences, especially in AI-driven healthcare technologies. Interested areas in include oncology, precision medicine, AI-enabled drug discovery and healthcare SaaS.
There is no specific requirement for the company and management team. The firm is open to working with both experienced and new entrepreneurs on a case-by-case basis.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Europe-Based VC Invests Up to €12M in Therapeutics Companies, Also Working as a Company Builder in Promising Early-Stage Project
A firm with offices in Europe currently manages a fund that focuses on investments in Europe-based therapeutics and medical innovation. The firm invests in Europe, and typically allocates €5 to €12 million equity to each portfolio company, generally over several tranches.
The firm invests in therapeutics ventures. The firm is agnostic regarding technologies and indication areas and invests in companies with assets 12 months or less to the clinic, as well as assets in phase 1 or 2. (i.e Series A and Series B)
Moreover, the firm is a company builder, identifying academic projects with potential for company creation. The company has developed a specific model of collaboration between the academic, the firm and an industrial to create companies.
The firm prefers to invest in companies that can present an exit opportunity in 3-5 years, usually through a pharmaceutical industry partnership.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Corporate Venture Arm of Global Company Makes Strategic Investments in Companies Dedicated to Human Nutritional Health
The corporate venture capital arm of a global science-based company active in health, nutrition and materials makes equity investments into seed and venture stage companies generally taking less than 25% ownership. The firm makes allocations ranging from a few hundred thousand dollars to $5 million initially with additional capital held for future financing rounds. The firm is looking to make approximately 5-10 investments over the next 6-9 months with +10 being made over the next 2 years. The firm invests in companies located around the globe with a focus on the U.S., Europe and Israel.
The firm is looking for materials science companies in orthopedics and soft tissue repair. The firm also actively invests in human nutritional health, with a specific focus on companies active in personalized nutrition, and companies developing nutritional products. While the firm has invested in companies all the way from seed to PIPE, they generally invest into companies that have products in development or early stage commercialization.
The firm highly values experience in a firms management team and generally looks to take a board seat and play an active role in its portfolio companies. The firm is looking for companies that are interested in cooperation/alignment with relevant businesses of the parent company.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Global Alternative Asset Manager Invests Up to $50M in Life Science Companies of All Stages of Development, Most Interested in Disruptive Therapeutics
A diversified, global, alternative asset manager with multiple offices across the globe has billions of dollars under management. The firm is invested equally in the private and public markets, and within the private markets, the firm seeks to invest across the entire private healthcare company lifecycle, from seed to cross-over. Initial check sizes can range from $5 – 50m and will largely depend on the stage of the company. With seed stage companies, the firm can invest $1-5m. In general, the firm ascribes to the approach of doubling the size of their prior round investment in each subsequent round (from Seed -> Series A -> Series B -> Series C -> IPO), subject to milestone achievement. The firm is currently focused on USA and Western European opportunities.
The firm’s primary investment focus is disruptive therapeutics-focused companies. The firm is most interested in genetic medicines (DNA, RNA, protein-targeted therapies including gene therapy, gene editing, oligonucleotides, and small molecule approaches), precision/targeted oncology (DNA damage repair/synthetic lethality, driver/resistance mechanisms), differentiated immunotherapies (gamma-delta T-cell-targeted, bispecific T-cell engagers, new efforts at drugging difficult checkpoints/targets), CNS disorders and autoimmune disorders (new targets of interest). The firm may consider therapeutics indications outside of CNS, oncology, and autoimmune disease on a much more selective basis. In terms of stage of development, the firm is open to pre-clinical opportunities from the lead optimization phase and beyond (discovery phase will be considered too early). The firm may consider opportunities outside of therapeutics including medical devices, diagnostics, tools and digital health, but will be much more selective.
The firm has no particular company or management team requirements. The firm is willing to lead rounds but can act as a follow-on – the firm may seek board representation when acting as the lead investor. The firm seeks to hold shares of their private company investments long after their successful IPO.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 